Aadi Bioscience Inc

Company Profile

aadi bioscience inc. (aadi), is a rapidly growing biopharmaceutical company focused on the development and commercialization of precision medicines targeted to rare genomic alteration-driven cancers. aadi’s lead asset, fyarrotm (sirolimus albumin-bound nanoparticles for injectable suspension), is an mtor inhibitor targeting cancers driven by genetic alterations in mtor pathway genes. supported by leading healthcare investors, aadi is currently preparing for launch of fyarro in advanced malignant pecoma, a rare type of sarcoma with no previously approved therapies. aadi’s world class leadership team is comprised of industry veterans from top biotech companies who have proven track records of bringing blockbuster products to market. a science-first mindset and entrepreneurial spirit is in our genes. aadi’s vision to become a leading precision oncology company is further supported by ongoing work in tumor-agnostic biomarker-driven populations (e.g., pan tumor tsc1/2 alterations) and n